MétaCan
Menu
Back to cohort
Record W2551114644 · doi:10.1186/s13058-016-0768-3

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

2016· article· en· W2551114644 on OpenAlexafffund
Timothy R. Rebbeck, Tara M. Friebel, Nandita Mitra, Fei Wan, Stephanie Chen, Irene L. Andrulis, Paraskevi Apostolou, Norbert Arnold, Banu Arun, Daniel Barrowdale, Javier Benı́tez, Raanan Berger, Pascaline Berthet, Åke Borg, Saundra S. Buys, Trinidad Caldés, Jonathan Carter, Jocelyne Chiquette, Kathleen Claes, Fergus J. Couch, Cezary Cybulski, Mary B. Daly, Miguel de la Hoya, Orland Dı́ez, Susan M. Domchek, Katherine L. Nathanson, Katarzyna Durda, D. Gareth Evans, Lenka Foretová, Eitan Friedman, Debra Frost, Patricia A. Ganz, Judy E. Garber, Gord Glendon, Andrew K. Godwin, Mark H. Greene, Jacek Gronwald, Eric Hahnen, Emily Hallberg, Ute Hamann, Thomas van Overeem Hansen, Evgeny N. Imyanitov, Claudine Isaacs, Anna Jakubowska, Ramūnas Janavičius, Katarzyna Jaworska–Bieniek, Esther M. John, Beth Y. Karlan, Bella Kaufman, kConFab Investigators, Ava Kwong, Yael Laitman, Christine Lasset, Conxi Lázaro, Jenny Lester, Niklas Loman, Jan Lubiński, Siranoush Manoukian, Gillian Mitchell, Marco Montagna, Susan L. Neuhausen, Heli Nevanlinna, Dieter Niederacher, Robert L. Nussbaum, Kenneth Offit, Edith Oláh, Olufunmilayo I. Olopade, Sue K. Park, Marion Piedmonte, Paolo Radice, Christine Rappaport, Matti A. Rookus, Caroline Seynaeve, Jacques Simard, Christian F. Singer, Penny Soucy, Melissa C. Southey, Dominique Stoppa‐Lyonnet, Grzegorz Sukiennicki, Csilla I. Szabo, Mariella Tancredi, Manuel R. Teixeira, Soo‐Hwang Teo, Mary Beth Terry, Mads Thomassen, Laima Tihomirova, Marc Tischkowitz, Amanda E. Toland, Aleksandra Tołoczko‐Grabarek, Nadine Tung, Elizabeth J. van Rensburg, Danylo Villano, Shan Wang‐Gohrke, Barbara Wappenschmidt, Jeffrey N. Weitzel, Jamal Zidan, Kristin K. Zorn, Lesley McGuffog, Douglas F. Easton, Georgia Chenevix‐Trench, Antonis C. Antoniou, Susan J. Ramus

Bibliographic record

VenueBreast Cancer Research · 2016
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsMcGill UniversityUniversité LavalUniversity of TorontoCentre hospitalier universitaire de QuébecHôpital du Saint-SacrementLunenfeld-Tanenbaum Research InstituteMount Sinai Hospital
FundersNational Cancer InstituteNational Center for Advancing Translational SciencesMedical Research Councillékařská fakulta Univerzity KarlovyLiga Portuguesa Contra o CancroNational Health and Medical Research CouncilInstitut National Du CancerNIH Office of the DirectorDeutsche KrebshilfeJewish General HospitalUniversità degli Studi di TorinoUniversità degli Studi di FirenzeNederlandse Organisatie voor Wetenschappelijk OnderzoekEuropean Regional Development FundNational Breast Cancer FoundationCanadian Breast Cancer Research AllianceMemorial Sloan-Kettering Cancer CenterNRG OncologyUniversity of PennsylvaniaMinistère du Développement Économique, de l’Innovation et de l’ExportationNational Institutes of HealthDavid F. and Margaret T. Grohne Family FoundationMcGill UniversityUniversity of California, San FranciscoMinistero della SaluteCancer Association of South AfricaSusan G. Komen for the CureBeth Israel Deaconess Medical CenterUniverzita Karlova v PrazeCancer Research UKMinistero dello Sviluppo EconomicoAmerican Cancer SocietyStop CancerCancer AustraliaOvarian Cancer Research FundIstituto Oncologico VenetoLietuvos Mokslo TarybaCanadian Institutes of Health ResearchFundación Mutua MadrileñaBreast Cancer Research Foundation
KeywordsLoss of heterozygosityMutationMedicineInternal medicineBreast cancerHeterozygote advantageCancerOncologyGastroenterologyGeneticsBiologyGeneAllele

Abstract

fetched live from OpenAlex

BACKGROUND: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. RESULTS: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. CONCLUSIONS: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.606
Threshold uncertainty score0.272

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.371
Teacher spread0.337 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations73
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueBreast Cancer ResearchSame topicBRCA gene mutations in cancerFrench-language works237,207